Entera Bio announced that post-hoc data from its Phase 2 clinical trial of EB613, an oral osteoporosis treatment, has been selected for two presentations at the ASBMR 2026 Annual Meeting, including a Plenary Poster. This indicates positive findings from the analysis, potentially strengthening the drug's profile as it progresses towards a Phase 3 trial.
Entera Bio (ENTX) announced that post-hoc data from its Phase 2 trial of EB613, an oral anabolic treatment for osteoporosis, will be presented at the prestigious ASBMR 2026 Annual Meeting. The selection for a Plenary Poster presentation suggests the data is highly regarded by the scientific community, indicating promising results, particularly regarding enhanced anabolic effects in high-risk patients. This is a positive development for ENTX, as it provides further validation for EB613 and could generate increased interest from potential partners or investors as the company plans for a Phase 3 trial. While the meeting is in 2026, the announcement now provides a short-term positive sentiment boost and long-term validation for the drug's potential, reducing perceived development risk.